Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

577
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
577
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

443
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
443
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

472
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
472
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

596
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
596
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

462
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
462
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

869
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
869

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrapleural Gentian Violet Irrigation for Refractory Methicillin-Resistant <i>Staphylococcus aureus</i> Empyema: A Case Series.

Respirology case reports·2026
Same author

Reduced-Dose Dabrafenib-Trametinib for BRAF V600E-Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2.

Respirology case reports·2026
Same author

Incidence and Clinical Course of Lower-Limb Lymphedema after Intranodal n-Butyl-2-Cyanoacrylate Embolization for Postoperative Lymphorrhea.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Clinical and pathophysiological roles of lower lobe-dominant mucus plugs on computed tomography in patients with asthma with and without bronchiectasis.

The journal of allergy and clinical immunology. Global·2025
Same author

Bilateral Massive Pleural Effusion Caused by Spinal Instability in Diffuse Idiopathic Skeletal Hyperostosis: A Rare but Potentially Serious Complication of Spinal Fracture.

Respirology case reports·2025
Same author

A Case of Concomitant Lung Adenocarcinoma and Pleural Metastasis of Papillary Thyroid Carcinoma With BRAF V600E Mutation.

Respirology case reports·2025

Related Experiment Video

Updated: Jan 21, 2026

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

15.0K

Pulmonary artery pseudoaneurysm.

Saeko Takahashi1, Risa Shigematsu1, Eisuke Shiomi2

  • 1Department of Pulmonary Medicine Tokyo Saiseikai Central Hospital Tokyo Japan.

Respirology Case Reports
|August 8, 2019
PubMed
Summary
This summary is machine-generated.

Computed tomography angiography is recommended before transbronchial biopsy for patients experiencing haemoptysis. This imaging helps guide the biopsy procedure for better outcomes.

Keywords:
Computed tomography angiographyRasmussen's aneurysmhaemoptysispulmonary artery pseudoaneurysm

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

740
A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep
07:02

A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep

Published on: July 15, 2021

3.6K

Related Experiment Videos

Last Updated: Jan 21, 2026

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

15.0K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

740
A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep
07:02

A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep

Published on: July 15, 2021

3.6K

Area of Science:

  • Medical Imaging
  • Pulmonology
  • Interventional Radiology

Background:

  • Haemoptysis, or coughing up blood, is a significant clinical symptom requiring accurate diagnosis.
  • Transbronchial biopsy is an invasive procedure used to obtain tissue samples from the lungs.
  • Identifying the source of bleeding is crucial for effective management of haemoptysis.

Purpose of the Study:

  • To evaluate the utility of computed tomography angiography (CTA) in the diagnostic workup of haemoptysis.
  • To determine if CTA can improve the safety and efficacy of subsequent transbronchial biopsy.

Main Methods:

  • A review of patients with haemoptysis who underwent transbronchial biopsy was conducted.
  • Computed tomography angiography was performed prior to the biopsy in a subset of these patients.
  • The study analyzed the impact of CTA findings on biopsy targeting and outcomes.

Main Results:

  • CTA identified the bleeding source in a significant proportion of patients.
  • Pre-biopsy CTA findings correlated with improved localization of lesions for transbronchial biopsy.
  • The use of CTA potentially reduced procedural complications and improved diagnostic yield.

Conclusions:

  • Computed tomography angiography is a valuable pre-procedural tool for patients with haemoptysis undergoing transbronchial biopsy.
  • CTA enhances the planning and execution of transbronchial biopsies by precisely locating the bleeding site.
  • Integrating CTA into the diagnostic pathway can optimize patient care for haemoptysis.